
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed |
AstraZeneca plc (NASDAQ: AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ...
LONDON (Reuters) – AstraZeneca has signed a licence agreement with a small UK-based biotech company for a slate of COVID antibody therapies, the Anglo-Swedish pharmaceutical giant said on Tuesday.
AstraZeneca Plc (NASDAQ: AZN) posted full results from the positive MANDALA Phase 3 trial of PT027, an albuterol/budesonide fixed-dose combination rescue medication in patients with asthma. The data...
BURLINGAME, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Accumulus Synergy, a nonprofit organization working to develop an information and data exchange platform aimed at transforming how drug...
Investing.com – U.K. equities were higher at the close on Wednesday, as gains in the Industrial Metals & Mining, Oil & Gas Producers and Life Insurance/Assurance sectors propelled shares higher. At...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Veru Suggested By FDA To Submit Emergency Use Request For Sabizabulin In COVID-19 In a Pre-EUA...
Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV). Results from the Phase 3 MELODY...
The FDA has approved AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast...
The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review